key: cord-0973987-buhq3omf
authors: Takagi, Hisato
title: Systematic review of the prevalence of current smoking among hospitalized COVID‑19 patients in China: could nicotine be a therapeutic option?
date: 2020-08-16
journal: Intern Emerg Med
DOI: 10.1007/s11739-020-02473-2
sha: 94ae2544c7099e20f5557a78b985fdd236e5233f
doc_id: 973987
cord_uid: buhq3omf

nan

We read with great interest the article by Farsalinos et al. [1] recently published in Internal and Emergency Medicine. The review [1] of 13 studies enrolling a total of 5960 hospitalized coronavirus disease 2019 (COVID-19) patients in China revealed unusually lower (approximately one-fourth) smoking prevalence in COVID-19 cases than that in the general population. Recent meta-analyses [2, 3] , however, demonstrated that smoking was associated with worse prognosis and mortality in patients with COVID-19. To determine whether COVID-19 prevalence is modulated by smoking prevalence, meta-regression of Japanese prefectural data was herein conducted.

In each Japanese prefecture, the following was extracted: (1) number of confirmed COVID-19 cases on 15 June 2020 from the "Ministry of Health, Labour and Welfare" (https ://www.mhlw.go.jp/conte nt/10906 000/00064 0393.pdf); (2) smoking prevalence (%) in 2016 (latest survey) from the "National Cancer Center Japan" (https ://ganjo ho.jp/reg_stat/ stati stics /dl/index .html#smoki ng); and (3-1) population per 1-km 2 inhabitable area (in 2018), proportion (%) of males and < 15-year/≥ 65-year subjects (in 2018), prevalence (/100 thousands) of neoplasm, type 2 diabetes mellitus, and essential hypertension (in 2017), (3-4) yearly average air temperature (°C), total sunshine hours (h), total precipitation (mm), and average relative humidity (%) (in 2018), (3) (4) (5) Table S1 ). To adjust for prefectural population density, COVID-19 prevalence was defined as the number of COVID-19 cases divided by the population per 100-km 2 inhabitable area. Univariable (including smoking prevalence as only a covariate) and multivariable (including all the above-mentioned parameters as covariates) random-effects meta-regression was performed using OpenMetaAnalyst (https ://www.cebm.brown .edu/ openm eta/index .html). A meta-regression graph depicted COVID-19 prevalence (plotted as logarithm-transformed prevalence on the Y-axis) as a function of smoking prevalence (plotted on the X-axis).

A slope of the univariable meta-regression line was significantly positive (coefficient, 0.319; 95% confidence interval [CI] 0.148-0.490; p < 0.001; Fig. 1 ), which indicated that COVID-19 prevalence increased significantly as smoking prevalence increased. The slope was also significantly positive (coefficient, 0.321; 95% CI 0.093-0.549; p = 0.006) even in multivariable meta-regression including all the 22 covariates together ( Table 1) .

The present meta-regression suggests a positive association of smoking prevalence with COVID-19 prevalence independent of various examined covariates. Remarkably lower current-smoking prevalence in hospitalized COVID-19 patients (6.5%; 95% CI 4.9-8.2%) than that in the general population (26.6%) in China (2018 Global Adult Tobacco Survey, https ://www.who.int/docs/defau lt-sourc e/wpro---docum ents/count ries/china /2018-gats-china -facts heetcn-en.pdf?sfvrs n=3f4e2 da9_2) has been reported in the article by Farsalinos et al. [1] , which could be explained carbon monoxide, and menthol) is experimentally known to positively modulate the immune system and may exert both harmful and beneficial influences [5] . The main limitations of the present analysis included relatively small number of COVID-19 cases in each prefecture and latest survey of smoking prevalence 4 years before the study period investigating COVID-19 prevalence in 2020. It should be noted that the present results do not denote directly that smokers are at high risk for COVID-19. The present findings demonstrate simply that the COVID-19 prevalence is higher in the Fig. 1 Meta-regression graph depicting COVID-19 prevalence (plotted as logarithmtransformed prevalence on the Y-axis) as a function of smoking prevalence (plotted on the X-axis) prefecture where smoking prevalence is higher. However, the present results could be strengthened and explained by the reported association of smoking with worse prognosis and mortality in COVID-19 patients [1, 2] .

In conclusion, smoking may be independently associated with COVID-19, which should be confirmed by further experimental, clinical and epidemiological investigations.

Conflict of interest The authors declare that they have no conflict of interest.

Informed consent Not applicable.

Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

The impact of COPD and smoking history on the severity of Covid-19: a systemic review and meta-analysis

Nicotine and the renin-angiotensin system

COVID-19: counter-intuitive data on smoking prevalence and therapeutic implications for nicotine